Data from the Survey of Unmet Needs in Chronic Myeloid Leukemia (CML SUN) trial show that quality of life (QOL) and shared decision-making are priorities for patients, said Fabian Lang, MD, of Goethe University Hospital in Frankfurt, Germany.
Data from the Survey of Unmet Needs in Chronic Myeloid Leukemia (CML SUN) trial show that quality of life (QOL) and shared decision-making are priorities for patients, said Fabian Lang, MD, of Goethe University Hospital in Frankfurt, Germany.
Transcript
What are some of the main points that health care providers and health systems can take away from the CML SUN trial results?
The CML SUN trial showed that, for example, fatigue is a quite present problem in these patients, which we were not much aware of. So, this is something we've got to get a handle on, which is difficult to evaluate, difficult to treat, and difficult to talk about. And what we've also seen is that doctors are mainly focused on BCR-ABL levels, which means numbers, in order to conduct and treat the patients. But, on the other hand, patients are more focused on things like quality of life, daily problems, and they are mainly focused on that. It is something which is quite true across all line of therapies.
And in the end, we also found that most of the patients do not have the feeling that a shared decision-making is taking place. So doctors tend to to tell the patients how therapy works and do not propose multiple therapies or discuss the therapies with the patients, and this is also something which comes through over all lines of therapy.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Adapting ACA Access Amid Medicaid Transition and Policy Reversals: Molly Dean
February 19th 2025As enrollment shifts to the Affordable Care Act (ACA) marketplace following the unwinding of Medicaid and the Trump administration begins to implement health policy changes, Molly Dean, MSW, Siftwell's policy advisor, shares insight on how to adapt.
Read More
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Adapting ACA Access Amid Medicaid Transition and Policy Reversals: Molly Dean
February 19th 2025As enrollment shifts to the Affordable Care Act (ACA) marketplace following the unwinding of Medicaid and the Trump administration begins to implement health policy changes, Molly Dean, MSW, Siftwell's policy advisor, shares insight on how to adapt.
Read More
2 Commerce Drive
Cranbury, NJ 08512